Baidu
map

央视报道!药师收入将上升

2019-03-26 小婉 赛柏蓝

据悉,药师立法已列入国家卫生立法计划,我国也将在部分公立医疗机构开展药事服务费试点工作,每张处方拟收费4元。

据悉,药师立法已列入国家卫生立法计划,我国也将在部分公立医疗机构开展药事服务费试点工作,每张处方拟收费4元。

▍央视公布:药事服务费,每张处方4元

央视新闻称,在现行机制下,药师没有足够的审方权,也没有相应的经费,来支持药师向患者提供用药咨询服务指导,这导致药师工作难度大、患者用药安全性得不到充分保障。

央视记者从相关部门了解到,为了改变这一现状,部分公立医疗机构将启动药事服务费试点工作。

目前,我国药师由两部分组成:一部分由卫生健康部门主管;另一部分由药品中监管部门管理。存在着管理体系二元化,药师队伍数量整体不足,职责定位和权利义务不够清晰,执业水平有待提高等问题。

北京市医院管理局总药师赵志刚对此表示,我国药师服务存在两大问题:第一,目前为止,我国有将近90万的药师队伍,但是药师的数量相对国际上的每万人所拥有的药师数量,远远不足;第二,药师的素质、能力也参差不齐,药学服务存在服务不充分、服务不均衡等现象。这些现象要改变,必须要有法律的保障。

央视新闻称,据悉,药师立法已列入国家卫生立法计划。药师在医疗服务体系中扮演着重要角色,为药师服务支付报酬是一种国际通行的普遍形式。

事实上,在国外,许多国家实行医药分业制度,医师专职于疾病诊断和开具处方,药师依据医师处方调剂药品,并提供用药指导等服务,分为门诊药事服务费和住院药事服务费。

我国也将在部分公立医疗机构开展药事服务费试点工作,每张处方拟收费4元。

▍药事服务费,规避大处方

事实上,对药事服务费的讨论一直存在。

今年“两会”期间,全国人大代表李燕就提出了相关的建议:具有药学专业技术优势的药师,可向患者专业的用药服务,指导患者进行自我用药管理,缓解门诊就诊压力。

此外,要进一步明确建立药师服务收费项目和收费标准。药师专业技术服务费时费力,但大部分地区医疗机构选择将药事服务费与其他医务人员的服务一起打包收取,并不能充分体现药师的专业技术服务价值。

一项来自中国临床安全用药检测网的用药错误报告显示,其中80%的用药错误事药师在审方和双核对工作时发现并规避的;一项对临床药师参与的肠外处方干预的研究透露,患者营养治疗日均费用从1021±218元降至860±176元,缩短了平均住院日。

因此,良好的药事服务不仅可以保障患者的用药安全,也可以一定程度上规避大处方,控制不合理医药费用的增长。

▍药事服务费,能否收得到?

最早,是发改委、卫生部等五部委于2010年2月23日对外公布《关于公立医院改革试点的指导意见》中指出:今后要通过实行药品购销差别加价,设立药事服务费等多种方式,逐步取消药品加成的管理。

但在实施过程中,存在着一些问题,以往在以药养医的体制下,药师的作用被药品加成所掩盖,只是做一些简单的药工工作,如执行收费、核对与发药。这个时候,在医师和药师之间进行合理的分工,分清各自的主动服务项目,提高诊疗与用药的水平就变的十分重要。

曾有学者提出类似的观点,其在《设立药事服务费存在的问题及建议》中提出:在正常的制度设计中,医院的医师和药师是平等的,两者之间应该是互相监督、彼此协作。但在现行体制下,药师的地位和作用被弱化和扭曲。

既没有足够的审方权,也没有配套的经费支持其向患者提供药事服务,这导致药师的作用被忽视了。

此外,有知情人士向赛柏蓝透露:现在一个很大的问题是药事服务费比较难收起来。一方面,比起医生,患者更难承认药师的价值,如果将药品加成收入全部转化为“药事服务费”和“调高医疗服务价格”,患者是不会接受的;另一方面,如果是医保来支付,只有药师对医保控费起到很明显的作用,医保才会给。

此次央视公布,要推进药事服务费,还确定到每个处方4元,这是个强有力的信号。但此后更细节的政策出台,我们还需等待。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=363635, encodeId=6ea9363635ac, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Wed Mar 27 14:57:53 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363566, encodeId=71ab3635660b, content=很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/18b71bb1fba9327f1f9096be45069b90.jpg, createdBy=f6942575622, createdName=Tary, createdTime=Tue Mar 26 08:45:32 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363565, encodeId=791d36356517, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/18b71bb1fba9327f1f9096be45069b90.jpg, createdBy=f6942575622, createdName=Tary, createdTime=Tue Mar 26 08:45:20 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363559, encodeId=2abd36355940, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Mar 26 07:31:38 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363555, encodeId=053f36355579, content=好事,技术价值得到体现, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4461587544, createdName=sxh96, createdTime=Tue Mar 26 07:01:44 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363548, encodeId=1b5c363548ef, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Mar 26 05:17:45 CST 2019, time=2019-03-26, status=1, ipAttribution=)]
    2019-03-27 12543c13m83暂无昵称

    谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=363635, encodeId=6ea9363635ac, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Wed Mar 27 14:57:53 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363566, encodeId=71ab3635660b, content=很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/18b71bb1fba9327f1f9096be45069b90.jpg, createdBy=f6942575622, createdName=Tary, createdTime=Tue Mar 26 08:45:32 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363565, encodeId=791d36356517, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/18b71bb1fba9327f1f9096be45069b90.jpg, createdBy=f6942575622, createdName=Tary, createdTime=Tue Mar 26 08:45:20 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363559, encodeId=2abd36355940, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Mar 26 07:31:38 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363555, encodeId=053f36355579, content=好事,技术价值得到体现, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4461587544, createdName=sxh96, createdTime=Tue Mar 26 07:01:44 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363548, encodeId=1b5c363548ef, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Mar 26 05:17:45 CST 2019, time=2019-03-26, status=1, ipAttribution=)]
    2019-03-26 Tary

    很好,值得学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=363635, encodeId=6ea9363635ac, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Wed Mar 27 14:57:53 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363566, encodeId=71ab3635660b, content=很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/18b71bb1fba9327f1f9096be45069b90.jpg, createdBy=f6942575622, createdName=Tary, createdTime=Tue Mar 26 08:45:32 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363565, encodeId=791d36356517, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/18b71bb1fba9327f1f9096be45069b90.jpg, createdBy=f6942575622, createdName=Tary, createdTime=Tue Mar 26 08:45:20 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363559, encodeId=2abd36355940, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Mar 26 07:31:38 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363555, encodeId=053f36355579, content=好事,技术价值得到体现, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4461587544, createdName=sxh96, createdTime=Tue Mar 26 07:01:44 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363548, encodeId=1b5c363548ef, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Mar 26 05:17:45 CST 2019, time=2019-03-26, status=1, ipAttribution=)]
    2019-03-26 Tary

    很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=363635, encodeId=6ea9363635ac, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Wed Mar 27 14:57:53 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363566, encodeId=71ab3635660b, content=很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/18b71bb1fba9327f1f9096be45069b90.jpg, createdBy=f6942575622, createdName=Tary, createdTime=Tue Mar 26 08:45:32 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363565, encodeId=791d36356517, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/18b71bb1fba9327f1f9096be45069b90.jpg, createdBy=f6942575622, createdName=Tary, createdTime=Tue Mar 26 08:45:20 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363559, encodeId=2abd36355940, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Mar 26 07:31:38 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363555, encodeId=053f36355579, content=好事,技术价值得到体现, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4461587544, createdName=sxh96, createdTime=Tue Mar 26 07:01:44 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363548, encodeId=1b5c363548ef, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Mar 26 05:17:45 CST 2019, time=2019-03-26, status=1, ipAttribution=)]
    2019-03-26 txqjm

    谢谢了,学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=363635, encodeId=6ea9363635ac, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Wed Mar 27 14:57:53 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363566, encodeId=71ab3635660b, content=很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/18b71bb1fba9327f1f9096be45069b90.jpg, createdBy=f6942575622, createdName=Tary, createdTime=Tue Mar 26 08:45:32 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363565, encodeId=791d36356517, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/18b71bb1fba9327f1f9096be45069b90.jpg, createdBy=f6942575622, createdName=Tary, createdTime=Tue Mar 26 08:45:20 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363559, encodeId=2abd36355940, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Mar 26 07:31:38 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363555, encodeId=053f36355579, content=好事,技术价值得到体现, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4461587544, createdName=sxh96, createdTime=Tue Mar 26 07:01:44 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363548, encodeId=1b5c363548ef, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Mar 26 05:17:45 CST 2019, time=2019-03-26, status=1, ipAttribution=)]
    2019-03-26 sxh96

    好事,技术价值得到体现

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=363635, encodeId=6ea9363635ac, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Wed Mar 27 14:57:53 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363566, encodeId=71ab3635660b, content=很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/18b71bb1fba9327f1f9096be45069b90.jpg, createdBy=f6942575622, createdName=Tary, createdTime=Tue Mar 26 08:45:32 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363565, encodeId=791d36356517, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/18b71bb1fba9327f1f9096be45069b90.jpg, createdBy=f6942575622, createdName=Tary, createdTime=Tue Mar 26 08:45:20 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363559, encodeId=2abd36355940, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Tue Mar 26 07:31:38 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363555, encodeId=053f36355579, content=好事,技术价值得到体现, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4461587544, createdName=sxh96, createdTime=Tue Mar 26 07:01:44 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363548, encodeId=1b5c363548ef, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Mar 26 05:17:45 CST 2019, time=2019-03-26, status=1, ipAttribution=)]

相关资讯

JAMA:药师主导的患者教育有助于减少老年人的不合理用药?

2018年11月,发表于《JAMA》上的D-PRESCRIBE随机临床试验,考察了药师指导下的教育干预对老年患者停用不合理处方的影响。

北京便利店里可买药:需配备药师进行用药指导

昨日上午,位于工体东路的京客隆便利店的收银台后新增了三个特殊的货架,上面放着70多种非处方药品和医疗器械,包括感冒药、医用酒精、退烧贴等常见药品和医疗器械。北京青年报记者了解到,这是本市首个获批经营药品、医疗器械的便利店。北青报记者了解到,允许便利店按有关标准申请零售经营乙类非处方药、二类医疗器械是北京市近日出台的《关于进一步促进便利店发展的若干措施》(以下简称《措施》)中的新举措。这一政策打破之

严管辅助用药 药师的这个作用不可忽视

12月12日,国家卫健委发布《关于做好辅助用药临床应用管理有关工作的通知》(下称《通知》),对加强辅助用药管理,提高合理用药水平作出明确规定,这也说明了国家是下定决心严管辅助用药了。

大批非药店,将布局卖药!

今年,北京市又将在50家连锁便利店试点卖药、卖器械。接下来,将会有大批非药店布局卖药。

全国人大代表葛明华:医药分家后药师更多的参与临床用药安全工作

公立医院医改从一开始就强调推动“医药分家”,破除“以药养医”,让公立医院的药房回归公益性,随着改革的不断推进,大多数医院已经逐渐实现医药分家,那么,现在的医院、医生和药师角色有何变化呢?

无人售药铺开 药师被无视?!

无人售药铺开,药师被无视?其实真正值得可怕的是...... 1月3日,成都市药监局发布了《成都市自动售药机销售非处方药品管理规定(试行)》(以下简称《规定》)。

Baidu
map
Baidu
map
Baidu
map